Voriconazole Suspension while Breastfeeding

There are high number of clear evidence that breastfeeding provides best nutrition that you can give to your baby. It is also evident that lactation is good for mothers health as well. Evolution has designed breastfeeding in a way that it caters all nutritional need of your child. However modern medicine is quite new for evolution, that is why mothers body is not well prepared to filter unnecessary chemical found in medicines. It becomes a necessity to figure out which drug is safe and which drug is dangerous for your newborn while nursing. In this article we will understand function of Voriconazole Suspension and its suitability with breastfeeding.

Voriconazole is an azole antifungal drug indicated for use in the treatment of: Invasive aspergillosis (1.1) Candidemia (nonneutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds (1.2) Esophageal candidiasis (1.3) Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy (1.4) Voriconazole is indicated for use in patients 12 years of age and older in the treatment of the following fungal infections: 1.1 Invasive Aspergillosis In clinical trials, the majority of isolates recovered were Aspergillus fumigatus. There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1) and Clinical Pharmacology (12.4)]. 1.2 Candidemia in Non-neutropenic Patients and the Following Candida Infections: Disseminated Infections in Skin and Infections in Abdomen, Kidney, Bladder Wall, and Wounds [See Clinical Studies (14.2) and Clinical Pharmacology (12.4).] 1.3 Esophageal Candidiasis [See Clinical Studies (14.3) and Clinical Pharmacology (12.4).] 1.4 Serious Fungal Infections Caused by Scedosporium apiospermum (Asexual Form of Pseudallescheria boydii) and Fusarium spp. Including Fusarium solani, in Patients Intolerant of, or Refractory to, Other Therapy [See Clinical Studies (14.4) and Clinical Pharmacology (12.4).] Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.

Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers It is not known whether voriconazole is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from voriconazole, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.